IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients
Figure 2
Growth parameters progression during IGF1 treatment. The figure reports the increase/decrease in weights (a), height (b), and head circumference (c) in each patient for one year, starting from Day0, D0 (first day of treatment, before IGF administration). The measurements were taken at D90 (90 days after the first IGF1 administration), D180 (180 days after the first IGF administration, last day of IGF1 treatment), D270 (270 days after the first IGF administration), D365 (365 days after the first IGF administration). The dotted lines represent the start (D0) and the end (D180) of the treatment. Each patient is color-coded: S1: blue, S2: red, S3: green, S4: purple, S5: cyan, and S6: orange. (a) Changes in body weight are expressed in kgs. There is an increase in body weight for each patient, with the exception of S2, who after D90 shows a decrease in body weight. The increase between D0 and D90 is significant (Wilcoxon test). (b) Changes in height are expressed in cms. The patients show a significant increase in height between D0 and D90 (Wilcoxon test). (c) Changes in head circumference are expressed in cms. The patients show an initial—but not significant—increase in head circumference between D0 and D90.
